Please login to the form below

Not currently logged in
Email:
Password:

Vertex strikes Italian reimbursement deal for Orkambi

AIFA gives the go-ahead for the cystic fibrosis treatment

VertexVertex has struck a market access deal in Italy for its cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor).

The reimbursement agreement with the Italian Medicines Agency (AIFA) will, the Boston-based pharma company said, enable access for hundreds of people in the country.

Simon Bedson, senior vice president and international general manager at Vertex, said: “We are pleased to have reached this agreement on behalf of CF patients in Italy who have been waiting for this important medicine.”

The firm was light on the details of the deal, but said it would add to pricing European pricing and reimbursement agreements in Germany, Austria, Denmark, Ireland and Luxembourg.

However, there are a number of countries with which Vertex has not been able to come to an agreement, among them France and England, whose cost-effectiveness watchdog rejected the drug last year.

Publishing its final appraisal determination NICE said the £104,000 per patient price tag was "too high" for the drug’s “modest” short term benefit, but Vertex is still working on coming to an agreement.

Bedson said: “We continue negotiations with other countries including France and the United Kingdom, and we encourage these national health authorities and government to work quickly with us to achieve reimbursement for all patients who may benefit.”

Orkambi treats cystic fibrosis in patients that have two copies of the f508del mutation and the twice-daily oral is the first medicine to treat the underlying cause of the genetic disease.

Vertex has been involved in a CF research programme since 2000 as a part of collaboration with CFFT, a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

Article by
Gemma Jones

13th July 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....